Concerning therapeutic evaluation, a trial for HER2 positive GC was launched by scholars from China, intending to evaluate the HER2 targeted therapy by monitoring HER2 status in CTCs, HER2 amplifications in cfDNA, and therapy resistance-related gene status in both CTCs and cfDNA from before treatment to disease remission or progression. Here, ERBB2 is linked to gastric cancer.